CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$50.04
+1.60%Year over year
Reported trailing growth
- Revenue
- -63.6%
- EBITDA
- +8.8%
- EBIT
- -16.6%
- EPS
- +12.3%
- Free cash flow
- -14.8%
- Operating cash flow
- -13.8%
Forward estimates
Based on analyst estimates
- Revenue
- +511.6%
- EBITDA
- +24.8%
- EPS
- +21.9%
Three-year CAGR
- Revenue
- +100.4%
- EBITDA
- -62.6%
- EBIT
- -21.8%
- Net income
- -58.8%
- EPS
- -49.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026